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Abstract
Introduction and hypothesis Intravesical onabotulinumtoxinA
(Botox®) is effective for idiopathic overactive bladder (OAB)
symptoms. Our primary objective was to compare the efficacy
of onabotulinumtoxinA for women with de novo OAB after
midurethral sling (MUS) surgery and women with idiopathic
OAB.
Methods Women enrolled in this prospective study had idio-
pathic (n=53) or de novo (n=49) OAB symptoms after MUS,
with at least one episode of urgency urine incontinence per
day. OnabotulinumtoxinA (100 U) was administered in 20
intradetrusor injections. Postvoid residual volumes were
checked at 2, 4 and 12 weeks. Participants completed a 3-
day bladder diary and the King’s Health Questionnaire
(KHQ) before and 12 weeks after treatment.
Results After 12 weeks, 22 patients (41.5 %) in the idiopathic
OAB and 19 patients (38.8 %) in the de novo OAB groups
were completely dry. OnabotulinumtoxinA injections had a
significant benefit within both groups (p <0.001) to decrease
both the daily numbers of voids (−2.39 and −2.0) and incon-
tinence episodes (−1.38 and −1.44), with no significant
difference between groups. We observed an increase of mean
voided volume of >90 ml in both groups. Urinary retention
was observed in four patients.
Conclusions We observed similar improvement in OAB
symptoms after intravesical onabotulinumtoxinA injections
within both groups. The rates of retention and requirement
for catheterization even for women with a prior MUS were
acceptable. These observational data provide evidence that
onabotulinumtoxinA can effectively treat patients with OAB
following stress urinary incontinence surgery.
Keywords Botulinum toxin . De novoOAB .Midurethral
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Introduction
Midurethral slings (MUS) are widely used as first-line surgical
therapy for women with stress urinary incontinence (SUI).
Rates of surgery have sharply increased over the last decade
[1], with a recent estimate for the lifetime risk of SUI surgery
of 13.6 % [2]. With current demographic trends, it is expected
that the number of MUS surgeries performed will continue to
increase.
Overall, these minimally invasive procedures have a low
incidence of complications. It was described that similarly to
earlier procedures for SUI—e.g., Burch colposuspension—
insertion of an MUS may also be associated with the devel-
opment of urge urinary incontinence (UUI) and storage-
related lower urinary tract symptoms (LUTS). Reports indi-
cate that 6–8 % of women treated with MUS will develop de
novo overactive bladder (OAB) symptoms [3, 4].
New-onset storage LUTS significantly impact on subjec-
tive cure rates and patients’ satisfaction with these procedures
An abstract (submission: 2015-A-682-IUGA) with preliminary results of
this study was accepted for poster presentation orally (OP 059) at the
2015 IUGA Meeting in Nice, France.
* Pawel Miotla
pmiotla@wp.pl
1 2nd Department of Gynaecology, Medical University of Lublin, ul.
Jaczewskiego 8, 20-954 Lublin, Poland
2 Department of Epidemiology and Biostatistics; Department of
Urogynaecology, Imperial College London, London, UK
3 Department of Paediatric Nursing, Medical University of Lublin,
Lublin, Poland
Int Urogynecol J (2016) 27:393–398
DOI 10.1007/s00192-015-2839-x
[5]. The mechanisms leading to symptoms of de novo OAB
are still not well understood but may occur even after a first
MUS surgery with correct tape placement [6]. In some cases,
OAB symptoms may be attributed to excessive tension ap-
plied to the tape or its placement too close to the bladder neck
[7–9]. After tape malposition, patients are likely to benefit
from tape incision; however, most women will require phar-
macological treatment. There are limited data regarding the
efficacy of therapies, specifically in patients with de novo
OAB after MUS.
Symptoms of idiopathic overactive bladder (OAB) affect
∼17 % of women, and its prevalence increases with patient
age, achieving 30.9% in elderly patients [10]. One of the most
bothersome symptoms of OAB is UUI, followed by urgency
and frequency [11]. The standard pharmacological treatment
for idiopathic OAB starts with anticholinergic drugs or
mirabegron intake [12, 13]. Many patients with idiopathic
OAB cannot be adequately managed with orally administered
drugs. Recent evidence also suggests that antimuscarinic ther-
apy provides less subjective benefit for patients with de novo
compared with idiopathic OAB [14].
Intravesical injections of onabotulinumtoxinA or sacral
nerve stimulation are widely used third-line options for
OAB. The efficacy of onabotulinumtoxinA (100 U) in the
treatment of idiopathic OAB has been repeatedly shown in
randomized clinical trials (RCTs) [15, 16]. Compared with
placebo, it significantly decreases daily micturition episodes,
and the number of UUI episodes, and importantly also signif-
icantly improves health-related quality of life in patients with
idiopathic OAB [15–18]. However, no studies have tested the
benefits of onabotulinumtoxinA specifically for patients with
de novo OAB after MUS procedures. Hence, we designed a
study aiming to compare the efficacy and safety of intravesical
onabotulinumtoxinA injections in women with de novo and
idiopathic OAB. The primary endpoints were changes in daily
number of micturitions and UUI episodes from baseline to
week 12. Secondary endpoints were changes in voided vol-
ume, differences in pad use, and changes in King’s Health
Questionnaire (KHQ) scores compared with baseline. Safety
assessments included all common potential adverse events of
botulinum toxin, including urinary retention, increased
postvoid residual (PVR) volumes, and urinary tract infection
(UTI).
Materials and methods
The study protocol was approved by our Institutional Board
Review for the Medical University of Lublin, Poland. All
participating patients were counselled regarding potential ad-
verse effects of onabotulinumtoxinA; they gave written in-
formed consent. Inclusion criteria were as follows: nonpreg-
nant women >18 years of age; idiopathic OAB wet symptoms
or de novo OABwet symptoms (at least one urine leakage per
day and more than eight micturition daily); lack of efficacy (at
least 3 months) or intolerance to antimuscarinic therapy; stage
0 or 1 on the Pelvic Organ Prolapse Quantification (POP-Q)
scale.
Exclusion criteria were mixed urinary incontinence (MUI)
in the past; OAB symptoms before sling surgery; bladder-
outlet obstruction (BOO) after surgery [maximum flow (Qmax)
on uroflowmetry<15 ml/s]; UTI; neurologic disorders affect-
ing bladder function; PVR volume >100ml; contraindications
to onabotulinumtoxinA use; allergy to lidocaine; uncontrolled
systemic diseases; contraindications to clean intermittent self-
catheterization; previous prolapse or anti-incontinence sur-
gery (except midurethral sling surgery with transobturator ap-
proach; only one procedure in the past and at least 6 months
before onabotul inumtoxinA treatment) ; previous
onabotulinumtoxinA injections due to urological conditions.
All participants were of European descent. From November
2011 to June 2014, 53 patients with idiopathic and 49 with de
novo OAB after MUS surgery were enrolled. All women in
the MUS group had been treated with transobturator tapes (T-
sling, Polhernia) and were enrolled in our study a minimum of
6 months after that surgery. At enrollment, all patients had
been treated for at least 3 months with anticholinergics—ei-
ther without sufficient improvement in OAB symptoms, or
with treatment limited by adverse events.
Participants completed 3-day bladder diaries, including a
count of pads used. They also completed a validated transla-
tion of the KHQ for evaluation of incontinence-specific qual-
ity of life (QoL) impairment, and they finally underwent a
systematic clinical examination. Postvoid residual measure-
ments using abdominal ultrasound (US) were performed in
all patients before treatment. Urodynamic testing was assessed
to confirm OAB symptoms and exclude the possibility of
BOO and therefore the need for sling incision. Additionally
for the sling group, transvaginal US was performed as de-
scribed previously in order to exclude patients with tape mal-
position who could benefit from sling incision [8, 9]. Two
blinded evaluators reviewed outcome data before analyses.
Participants started with antibiotic prophylaxis (ciproflox-
acin 500 mg per os twice daily) for 1 day before the injection
procedure and continued for 5 days after treatment. Thirty
minutes before the procedure, all patients received a 100-ml
instillation of 2 % lidocaine intravesically through a Foley
catheter. Saline cystoscopy was performed using a 19-F rigid
cystoscope (Karl-Storz). OnabotulinumtoxinA (100 U) in
10 ml 0.9 % sodium chloride was administered in 20 injec-
tions during cystoscopy, sparing the trigone, using a 25-gauge
injeTAK 198 DIS needle (Laborie). The tip of needle was
inserted 3 mm into the bladder wall. Patients were discharged
2–3 h after injections and following a successful demonstra-
tion of voiding. PVR volumes were checked after 2 weeks, 1
month, and 3 months. Patients with elevated residual volumes
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(PVR>100ml) received extended antibiotic prophylaxis (e.g.,
nitrofurantoin 100 mg three times per day). Patients complet-
ed a further bladder diary and the KHQ after 3 months.
Statistical analysis was performed with Statistica
Statsoft, version 10 package, using the unpaired or paired
Student t test, the Mann–Whitney U test, and the χ2 test, as
appropriate. A p value<0.05 was considered statistically
significant throughout. The sample size was pragmatic,
but post hoc power calculations based on the observed
success rate, taking into account the decrease in mean
number of incontinence episodes and frequency of mictu-
ritions as primary endpoints and using the t test for paired
samples, showed >95 % power at a two-sided significance
level of 0.05 for each group.
Results
Patient demographics
Baseline demographic characteristics were similar between
groups, with the exception of higher parity among women
with a prior MUS (Table 1). One hundred and two patients
completed treatment and were available with 12 weeks of
follow-up (Fig. 1).
Clinical effectiveness
After 12 weeks, 22 (41.5 %) patients with idiopathic and
19 (38.8 %) with de novo OAB were completely dry on
their 3-day bladder diaries, and the rates of dryness did not
differ between groups (p>0.05). Taking into account that
all these patients had at least one episode of urine leakage
per day at baseline, these data support high effectiveness of
the procedure. OnabotulinumtoxinA injections significant-
ly decreased the mean number of daily micturitions, incon-
tinence episodes, and number of pads used, as well as in-
creasing mean voided volume per micturition in both
groups. Across all outcomes, efficacy was similar for pa-
tients with idiopathic and de novo OAB, with no statisti-
cally significant differences between groups (Table 2;
Figs. 2 and 3).
Quality of life
At the 12-week follow-up, participants in both groups reported
lower values in all questionnaire domains compared with base-
line (high KHQ scores represent greater QoL impairment).
There were statistically significantly improvements at 3 months
in each domain in both groups (p<0.001), including the Gen-
eral Health Perception domain. We found no statistically sig-
nificant differences in QoL improvement between groups ei-
ther for individual domains or for total KHQ score (Fig. 4).
Safety
The most frequently observed adverse event in both groups
was the increase in residual volume, which was usually
asymptomatic and clinically nonsignificant. Elevated residual
volumes were most prevalent during the US examination per-
formed 2 weeks after treatment. The number of patients with
elevated PVR volumes decreased from week 2 to week 12 in
both groups. The most severe adverse event was urinary re-
tention, which was observed in four patients (one in the
Table 1 Demographic
characteristics of patient groups Variable Idiopathic OAB (n=53) De novo OAB after MUS (n=49) p value
Age (years) 58.7±15.3 63.6±10.2 0.06
BMI (kg/m2) 29.1±5.3 30.1±5.0 0.12
Parity 1.01±1.53 1.75±2.53 <0.001
Previous hysterectomy 11 (20.75) 7 (14.3) 0.39
Continuous variables are mean±standard deviation; categorical variables are n (%)
BMI body mass index, OAB overactive bladder, MUS midurethral sling
Fig. 1 Study participants
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idiopathic group with a postvoid volume of 300 ml, and three
in the de novo OAB, two of whom had PVR>350 ml and one
310 ml); two cases in the de novo group required self-
catheterization for 1 month. In the other two patients, PVR
decreased to 250 ml and 280 ml after one week, respectively.
Urinary tract infections were rarely observed, at less than 4 %
in both groups. We did not observe any major complications,
requiring readmission or reoperation, in either group
(Table 3).
Discussion
We believe this study is the first to evaluate the effectiveness
of onabotulinumtoxinA specifically for patients with de novo
OAB symptoms after MUS surgery. Our results demonstrate
that the efficacy of onabotulinumtoxinA injections is compa-
rable with efficacy for idiopathic OAB, providing tape mal-
position is excluded. The primary endpoint of complete dry-
ness measured at 12 weeks, observed in almost 39 % of de
novo OAB patients, demonstrated a high cure rate for UUI,
with clinically relevant and statistically significant improve-
ments in all secondary outcomes.
Women in the de novo group reported reductions in both
the daily number of UUI episodes and the frequency of
voiding, with an increase in voided volume >90 ml. These
objective findings are similar to data from recent randomized
trials of onabotulinumtoxinA (100 U) injections in patients
with idiopathic OAB [15, 18].We also observed improvement
Table 2 Pre- and posttreatment clinical parameters in patients with idiopathic and de novo overactive bladder (OAB) who received intravesical
onabotulinumtoxinA injections
Parameters Idiopathic OAB (n=53) De novo OAB after MUS (n=49)
Number of micturitions/24 h (pretreatment) 10.89±1.43 10.94±1.34
Number of micturitions/24 h (posttreatment) 8.50±2.05 8.93±1.84
Number of UUI/24 h (pretreatment) 1.87±0.86 2.12±0.86
Number of UUI/24 h (posttreatment) 0.49±0.65 0.68±0.94
Volume voided (ml)/micturition (pretreatment) 202.3±30.0 199.0±35.7
Volume voided (ml)/micturition (posttreatment) 295.7±62.1 290.6±77.9
Number of incontinence pads used/24 h (pretreatment) 3.07±0.97 3.47±1.32
Number of incontinence pads used/24 h (posttreatment) 1.37±0.88 1.63±1.25
All data presented as mean±standard deviation. Differences between pre- and posttreatment values within each group were statistically significant
(all p<0.001). There were no statistically significant differences between groups
Fig. 2 Change from baseline in number of daily micturitions, urge
incontinence episodes, and pads used in patients with idiopathic and de
novo overactive bladder (OAB) at week 12 after onabotulinumtoxinA
injections. There were no statistically significant differences between
idiopathic vs de novo OAB groups
Fig. 3 Change from baseline in voided volume in patients with
idiopathic and de novo overactive bladder (OAB) at week 12 after
onabotulinumtoxinA injections. There was no statistically significant
difference between idiopathic and de novo OAB groups
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in all domains of the KHQ in both groups, and again our
results are consistent with published observations from large
RCTs investigating idiopathic OAB [15, 16].
We observed UTIs in 4 % of patients only, a rate consider-
ably lower than in previous clinical trials [15]. The incidence
of elevated PVR volumes was similar to results of previous
trials [15, 16]. Therefore, the low incidence of UTI may be
attributable to our routine use of antimicrobial prophylaxis
before and after cystoscopy and use of prophylaxis for all
patients with elevated PVR volumes.
We found only one previous comparative study assessing
the efficacy of pharmacological therapy in women with de
novo (n=110) and idiopathic (n=120) OAB [14]. Patients in
both groups were treated with 5 mg of solifenacin taken orally
once daily for 3 months. In that prior study, patients in the de
novo group reported significantly worse subjective and objec-
tive results after 3 months. More effective treatment options
are needed for patients with de novo OAB symptoms, and
overall, our results confirm the efficacy and safety of
onabotulinumtoxinA in this setting.
The strengths of our study include the excellent follow -up
achieved in a highly pragmatic and generalizable setting. Lim-
itations include the relatively small number of patients and
lack of placebo control. Lack of statistical significance for
comparisons between groups must therefore be interpreted
with caution considering the number of participants. Our find-
ings may be subject to bias from unmeasured confounding,
necessitating future randomized trials.
We observed that onabotulinumtoxinA injection was both
effective and safe for patients with de novo OAB after MUS
surgery, with comparable results to women with idiopathic
OAB. Injections increased voided volume, decreased urinary
frequency and number of UUI episodes, and improved QoL.
Although the study provides limited power to test differences
Fig. 4 Change from baseline in
quality of life in the King’s Health
Questionnaire at week 12 after
onabotulinumtoxinA injections.
Differences between pre- and
posttreatment values in each
investigated group were highly
statistically significant (all
p<0.001). There were no
statistically significant differences
between groups
Table 3 Incidence of adverse events at weeks 2 and 12 after onabotulinumtoxinA injections






De novo OAB after
MUS (n=49)
(at week 2)
De novo OAB after
MUS (n=49) (at week 12)
Urinary tract infection 2 (3.7) 1 (1.8) 2 (4.0) 1 (2.0)
Hematuria and/or leukocyturia 1 (1.8) 0 (0) 3 (6.1) 1 (2.0)
Weakness and fatigue 0 (0) 0 (0) 1 (2.0) 0 (0)
Residual urine volume <100 ml 20 (37.7) 5 (9.4) 13 (26.5) 7 (14.2)
Residual urine volume >100 ml and <200 ml 7 (13.2) 2 (3.7) 12 (24.5) 3 (6.1)
Residual urine volume >200 ml and <350 ml 1 (1.9) 0 (0) 1 (2.0) 0 (0)
Urine retention >350 ml 0 (0) 0 (0) 2 (4.0) 0 (0)
Differences between investigated groups were not statistically significant. Data presented as n (%)
OAB overactive bladder, MUS midurethral sling
Int Urogynecol J (2016) 27:393–398 397
in adverse events between groups, the rates of retention and
requirement for catheterization even among women with a
prior midurethral sling were acceptable. Patients with de novo
OAB must be warned about the potential increased risk of
urinary retention. These observational data provide evidence
that onabotulinumtoxinA injections can effectively treat pa-
tients with de novo OAB following incontinence surgery.
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